To include your compound in the COVID-19 Resource Center, submit it here.

IQWiG: Olysio offers 'major' benefit vs. Incivek

Germany's Institute for Quality and Efficiency in Healthcare said HCV drug Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE